An artificial intelligence-powered PD-L1 combined positive score (CPS) analyser in urothelial carcinoma alleviating interobserver and intersite variability.

Journal: Histopathology
PMID:

Abstract

AIMS: Immune checkpoint inhibitors targeting programmed death-ligand 1 (PD-L1) have shown promising clinical outcomes in urothelial carcinoma (UC). The combined positive score (CPS) quantifies PD-L1 22C3 expression in UC, but it can vary between pathologists due to the consideration of both immune and tumour cell positivity.

Authors

  • Kyu Sang Lee
    Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
  • Euno Choi
    Department of Pathology, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Republic of Korea.
  • Soo Ick Cho
    Department of Dermatology, Seoul National University College of Medicine, Seoul, South Korea.
  • Seonwook Park
    Lunit, Seoul, Republic of Korea.
  • Jeongun Ryu
    Lunit, Seoul, Republic of Korea.
  • Aaron Valero Puche
    Lunit, Seoul, Republic of Korea.
  • Minuk Ma
    School of Electrical Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea.
  • Jongchan Park
    Lunit Incorporated.
  • Wonkyung Jung
    School of Nursing, University of Washington, Seattle, Washington, USA.
  • Juneyoung Ro
    Lunit, Seoul, Republic of Korea.
  • Sukjun Kim
    Lunit, Seoul, Korea (the Republic of).
  • Gahee Park
    Lunit, Seoul, Korea (the Republic of).
  • Sanghoon Song
    Lunit, Seoul, Korea (the Republic of).
  • Chan-Young Ock
    Lunit, Seoul, Korea (the Republic of) jeannes@stanford.edu ock.chanyoung@lunit.io.
  • Gheeyoung Choe
    Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
  • Jeong Hwan Park
    Department of Pathology, Seoul National University College of Medicine and SMG-SNU Boramae Medical Center, Seoul, Korea.